Vertex Pharmaceuticals Incorporated VRTX Securities Lawsuit

Company:	Vertex Pharmaceuticals Incorporated
Ticker Symbol:	VRTX
Class Period:	May-7-12 to Jun-27-12
Date Filed:	Oct-22-12
Lead Plaintiff Deadline:	Dec-21-12
Court:	District of Massachusetts
Allegations:

New York, NY: A securities class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who acquired Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company") (NasdaqGS: VRTX) securities between May 7, 2012 and June 27, 2012.

On May 7, 2012, Vertex issued a press release claiming that patients who received two of its drugs during clinical trials showed significant improvement in their lung functions. Between May 7, 2012 and May 25, 2012, certain Vertex officers and directors sold over $22 million of their personally owned shares. Then, on May 29, 2012, Vertex issued a series of press releases in which it acknowledged that the results from its clinical trials were not as positive as previously indicated. These results were further restated on June 28, 2012. Upon this news, Vertex stock fell from a close of $61.11 on June 27, 2012, to a close of $51.18 on June 28, 2012.

If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.

Vertex Pharmaceuticals Incorporated VRTX Securities Fraud Legal Help

If you have suffered from financial losses, you may qualify for damages or remedies that may be awarded in a possible Vertex Pharmaceuticals Incorporated securities class action lawsuit. Please fill in our form on the right to submit your complaint for a free evaluation.